Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 4/20 | 0.63 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | DHODH | Q02127 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2205199 | 0.96 | PDE5A (0.62) | PDE5AHPGDHSD17B10MAPK1HTT | |
| SCHEMBL2205641 | 0.86 | PDE5A (0.60) | PDE5AHPGDHSD17B10MAPK1HTT | |
| SCHEMBL2205008 | 0.86 | PDE5A (0.57) | PDE5AHPGDHSD17B10MAPK1HTT | |
| SCHEMBL2208295 | 0.86 | PDE5A (0.56) | PDE5AHPGDHSD17B10MAPK1HTT | |
| SCHEMBL2206414 | 0.85 | PDE5A (0.59) | PDE5AHPGDHSD17B10MAPK1HTT | |
| SCHEMBL2205202 | 0.85 | PDE5A (0.61) | PDE5AHPGDHSD17B10MAPK1HTT | |
| SCHEMBL291420 | 0.84 | PDE5A (0.76) | PDE5AHPGDHSD17B10MAPK1HTT | |
| SCHEMBL2205026 | 0.83 | PDE5A (0.56) | PDE5AHPGDHSD17B10MAPK1HTT | |
| SCHEMBL2204095 | 0.82 | PDE5A (0.57) | PDE5AHPGDALDH1A1MAPTKDM4E | |
| SCHEMBL2209018 | 0.82 | PDE5A (0.57) | PDE5AHPGDHSD17B10MAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230468-A1 | FUSED HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-22 | — | — | US | claimed |
| US-20110230468-A1 | FUSED HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-22 | — | — | US | disclosed |
| US-7981881-B2 | Fused heterocyclic compounds and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| US-20080293650-A1 | Fused Heterocyclic Compounds and Use Thereof | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-27 | — | — | US | disclosed |
| US-7384937-B2 | Fused heterocyclic compounds and use thereof | BRISTOL-MYERS SQUIBB CO. (US) | 2008-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230468-A1 | FUSED HETEROCYCLIC COMPOUNDS AND USES THEREOF | MCL1, FPR1, LTC4S | PDE5A 3946/4885HPGD 252/4885HSD17B10 2118/4885 |
| US-20080293650-A1 | Fused Heterocyclic Compounds and Use Thereof | MCL1, FPR1, LTB4R | PDE5A 4015/4885HPGD 311/4885HSD17B10 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.